Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Recurrence 1Neoplasm, Residual 1Leukemia 1Graft vs Host Disease 1

Interventions

Cyclophosphamide 21fludarabine phosphate 13Cyclosporine 11Antilymphocyte Serum 11Peripheral Blood Stem Cell Transplantation 10Methotrexate 10Busulfan 10Cytarabine 9Filgrastim 8Radiotherapy 7Dexamethasone 7Whole-Body Irradiation 6Mycophenolic Acid 6Methylprednisolone 6Melphalan 6Exercise 6fludarabine 5Vincristine 5Daunorubicin 5Cord Blood Stem Cell Transplantation 5pegaspargase 4Rituximab 4Palliative Care 4Mercaptopurine 4Etoposide 4Early Intervention, Educational 4Blood Specimen Collection 4Asparaginase 4Alemtuzumab 4Thioguanine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Leukemia × Interferon alpha-2 × Clear all
NCT02185261 2018-06-07

Interferon α for the Therapy of Minimal Residual Disease

Peking University People's Hospital

Phase NA Unknown
81 enrolled
Other hematologic neoplasm

Graft vs Host Disease, Leukemia, Recurrence, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡